Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma

8 Sept 2022

Abstract excerpt

Autologous T cells transduced to express a high affinity T-cell receptor specific to NY-ESO-1 (letetresgene autoleucel, lete-cel) show promise in the treatment of metastatic synovial sarcoma, with 50% overall response rate. The efficacy of lete-cel treatment in 45 synovial sarcoma patients (NCT01343043) has been previously reported, however, biomarkers predictive of response and resistance remain to be better...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Sarcoma Diagnosis and Treatment
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36075914
DOI: 10.1038/s41467-022-32491-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcomaPMID 36075914Read ↗

Uzatresgene autoleucel autologous T-cell monotherapy for advanced solid tumors: SURPASS, a phase 1, open-label trialSemantic proximity Read ↗

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.Semantic proximity Read ↗

Distinct immunologic patterns of response and resistance to anti-PD-1/PD-L1-based immunotherapy in patients with soft tissue sarcoma.Semantic proximity Read ↗

Gene and Cell Therapy for Sarcomas: A ReviewSemantic proximity Read ↗

Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma PatientsSemantic proximity Read ↗

The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers.Semantic proximity Read ↗

Harnessing the lymphocyte meta-phenotype to optimize adoptive cell therapySemantic proximity Read ↗

Translation of oncolytic viruses in sarcomaSemantic proximity Read ↗

Combination of NY-ESO-1-TCR-T-cells coengineered to secrete SiRPα decoys with anti-tumor antibodies to augment macrophage phagocytosisSemantic proximity Read ↗

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task ForceSemantic proximity Read ↗

Blood and Tissue Biomarker Analysis in Dogs with Osteosarcoma Treated with Palliative Radiation and Intra-Tumoral Autologous Natural Killer Cell TransferSemantic proximity Read ↗

Exploiting the curative potential of adoptive T‐cell therapy for cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.